Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cinaciguat

Next Previous
Drug Profile

Cinaciguat

Alternative Names: BAY-582667

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antihypertensives; Carboxylic acids
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Decompensated heart failure

Most Recent Events

  • 25 Nov 2013 Discontinued - Phase-II for Decompensated heart failure in Canada, Croatia, Czech Republic, France, Finland, Germany, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Poland, Russia, Serbia, Slovenia, Spain, South Africa and the USA (IV)
  • 12 Nov 2013 No development reported - Phase-II for Decompensated heart failure in Canada, Croatia, Czech Republic, France, Finland, Germany, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Poland, Russia, Serbia, Slovenia, Spain, South Africa and the USA (IV)
  • 14 Mar 2011 Bayer terminates phase II trial (COMPOSE 2) in Decompensated heart failure in Germany and Ireland (NCT01067859)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top